H. R. 2438
IN THE HOUSE OF REPRESENTATIVES
May 19, 2015
Mr. Collins of New York introduced the following bill; which was referred to the Committee on Energy and Commerce
To amend the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs.
Broader application of Bayesian statistics and adaptive trial designs
Proposals for use of innovative statistical methods in clinical protocols for drugs and biological products
For purposes of assisting sponsors in incorporating adaptive trial design and Bayesian methods into proposed clinical protocols and applications for new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and biological products under section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary shall conduct a public meeting and issue guidance in accordance with subsection (b).
Guidance addressing use of adaptive trial designs and Bayesian methods
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs (in this subsection referred to as the
update and finalize the draft guidance addressing the use of adaptive trial design for drugs and biological products; and
issue draft guidance on the use of Bayesian methods in the development and regulatory review and approval or licensure of drugs and biological products.
The guidances under paragraph (1) shall address—
the use of adaptive trial designs and Bayesian methods in clinical trials, including clinical trials proposed or submitted to help satisfy the substantial evidence standard under section 505(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(d));
how sponsors may obtain feedback from the Secretary on technical issues related to modeling and simulations prior to—
completion of such modeling or simulations; or
the submission of resulting information to the Secretary;
the types of quantitative and qualitative information that should be submitted for review; and
recommended analysis methodologies.
Prior to updating or developing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patient advocacy organizations, and disease research foundations, through a public meeting to be held not later than 1 year after the date of enactment of this Act.
The Secretary shall publish—
the final guidance required by paragraph (1)(A) not later than 18 months after the date of the public meeting required by paragraph (3); and
the guidance required by paragraph (1)(B) not later than 48 months after the date of the public meeting required by paragraph (3).